EP1370240A4 - Neuroprotectants formulations and methods - Google Patents

Neuroprotectants formulations and methods

Info

Publication number
EP1370240A4
EP1370240A4 EP02733809A EP02733809A EP1370240A4 EP 1370240 A4 EP1370240 A4 EP 1370240A4 EP 02733809 A EP02733809 A EP 02733809A EP 02733809 A EP02733809 A EP 02733809A EP 1370240 A4 EP1370240 A4 EP 1370240A4
Authority
EP
European Patent Office
Prior art keywords
neuroprotectants
formulations
methods
neuroprotectants formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02733809A
Other languages
German (de)
French (fr)
Other versions
EP1370240A1 (en
Inventor
David P Hesson
Glenn D Frazer
Douglas Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuron Therapeutics Inc
Original Assignee
Neuron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Therapeutics Inc filed Critical Neuron Therapeutics Inc
Publication of EP1370240A1 publication Critical patent/EP1370240A1/en
Publication of EP1370240A4 publication Critical patent/EP1370240A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0464—Cerebrospinal fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0476—Oxygenated solutions
EP02733809A 2001-03-02 2002-02-28 Neuroprotectants formulations and methods Withdrawn EP1370240A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79888001A 2001-03-02 2001-03-02
US798880 2001-03-02
PCT/US2002/005885 WO2002078670A1 (en) 2001-03-02 2002-02-28 Neuroprotectants formulations and methods

Publications (2)

Publication Number Publication Date
EP1370240A1 EP1370240A1 (en) 2003-12-17
EP1370240A4 true EP1370240A4 (en) 2004-09-22

Family

ID=25174500

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02733809A Withdrawn EP1370240A4 (en) 2001-03-02 2002-02-28 Neuroprotectants formulations and methods

Country Status (2)

Country Link
EP (1) EP1370240A4 (en)
WO (1) WO2002078670A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312103T1 (en) 1999-01-25 2005-12-15 Nat Jewish Med & Res Center SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USES
JP2005508864A (en) 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター Oxidant scavengers for the treatment of diabetes or for use in transplantation or for induction of immune tolerance
JP4758641B2 (en) * 2003-12-12 2011-08-31 千寿製薬株式会社 α-Ketoamide derivative, process for producing the same, and use thereof
US7491705B2 (en) 2003-12-12 2009-02-17 Senju Pharmaceutical Co., Ltd. Alpha-ketoamide derivative, and production method and use thereof
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
AU2005224160A1 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
WO2006068199A1 (en) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. Metabolically stable 3-oxy-1,2,4-triazole derivatives
JP2006213611A (en) * 2005-02-02 2006-08-17 Suzuka Univ Of Medical Science Preventive or therapeutic agent for stroke or sequela of stroke containing 1-aminocyclopropane carboxylic acid or the like as main ingredient
PT1874311E (en) 2005-04-15 2011-11-25 Res & Innovation S P A A method for preventing, delaying or reverting abnormal amyloid deposition
ES2332846B1 (en) * 2007-10-26 2010-07-08 Grifols, S.A. USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS.
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
EP2803356A1 (en) * 2008-03-31 2014-11-19 Agency for Science, Technology and Research Method for treating neurological disorders with imidazolium and imidazolinium compounds
JP5608644B2 (en) * 2008-05-23 2014-10-15 ナショナル ジューイッシュ ヘルス Methods for treating damage associated with exposure to alkylated species
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US4840617A (en) * 1980-04-14 1989-06-20 Thomas Jefferson University Cerebral and lumbar perfusion catheterization apparatus for use in treating hypoxic/ischemic neurologic tissue
US5085630A (en) * 1980-04-14 1992-02-04 Thomas Jefferson University Oxygenated fluorocarbon nutrient solution
WO2000050058A1 (en) * 1999-02-26 2000-08-31 Marcus Keep Cerebrospinal and vascular pharmaceutical composition and process for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US5980480A (en) * 1996-07-11 1999-11-09 Cs Fluids, Inc. Method and apparatus for treating adult-onset dementia of the alzheimer's type
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US4840617A (en) * 1980-04-14 1989-06-20 Thomas Jefferson University Cerebral and lumbar perfusion catheterization apparatus for use in treating hypoxic/ischemic neurologic tissue
US5085630A (en) * 1980-04-14 1992-02-04 Thomas Jefferson University Oxygenated fluorocarbon nutrient solution
WO2000050058A1 (en) * 1999-02-26 2000-08-31 Marcus Keep Cerebrospinal and vascular pharmaceutical composition and process for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BHARDWAJ A. ET AL.: "Adenosine modulates N-Methyl-D-Aspartate-stimulated hippocampal nitric oxide production in vivo", STROKE, vol. 26, no. 9, September 1995 (1995-09-01), pages 1627 - 1633, XP009034612 *

Also Published As

Publication number Publication date
EP1370240A1 (en) 2003-12-17
WO2002078670A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
HK1068555A1 (en) New formulations and use thereof
AU2002357119A8 (en) Mitocidal compositions and methods
GB2359254B (en) Formulation
EP1420829A4 (en) Immunomodulatory compositions, formulations, and methods for use thereof
AU2003298738A8 (en) Liposomal formulations
EP1391212A4 (en) Oral preparations and supports for oral preparations
GB0000891D0 (en) Formulation
EP1370240A4 (en) Neuroprotectants formulations and methods
GB2380672B (en) Herbal formulation
AU2002357748A8 (en) Osteopontin-related compositions and methods
GB0111314D0 (en) Dermatological formulations
GB2378384B (en) Herbal formulation
GB2378385B (en) Herbal formulation
GB0125492D0 (en) Formulation
AU2003263895A8 (en) Contraceptive methods and formulations
AU2002359869A8 (en) Pak5-related compositions and methods
GB2396812B (en) Formulation
GB2375048B (en) Formulation
GB0115893D0 (en) Formulations
GB0116619D0 (en) Formulation
AU2002305940A1 (en) Neuroprotectants formulations and methods
GB0112497D0 (en) Formulation
NZ513664A (en) Long acting formulations
GB0107226D0 (en) Formulations
EG22944A (en) Systemic formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040811

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/28 B

Ipc: 7A 61K 47/08 B

Ipc: 7A 61K 38/38 B

Ipc: 7A 61K 9/107 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040901